文献速递妇科

超声引导下经皮微波消融治疗浆膜下子宫肌瘤

Ultrasound-Guided Percutaneous Microwave Ablation for Subserosal Uterine Myomas.
PubMed 文献 · J Minim Invasive Gynecol · 2018-06-28

前瞻性观察性研究纳入69例有症状的浆膜下子宫肌瘤患者,行超声引导下经皮微波消融。肌瘤平均体积从术前221.74 cm³分别降至术后3、6、12个月的87.24、46.68、38.05 cm³(均P<.001)。症状严重度评分从34.53降至12.74,健康相关生活质量评分从45.25升至78.48(均P<.001),无永久性损伤或致命并发症。

要点

  • 超声引导下经皮微波消融后肌瘤平均体积在3、6、12个月均较术前显著缩小(均P<.001)。
  • 症状严重度评分从34.53降至12.74,生活质量评分从45.25升至78.48(均P<.001),6和12个月保持稳定。
  • 本组未见永久性损伤或致命并发症;作者认为该疗法有前景,需更大样本及对照组进一步研究。

核心结论

  • 超声引导下经皮微波消融治疗浆膜下子宫肌瘤是一种有前景的治疗方法,但需更大样本量及设对照组的研究进一步验证。

研究设计与样本

  • 前瞻性观察性研究(加拿大任务组分类II-1),在一家教学医院(中国人民解放军总医院介入超声科)开展。
  • 纳入69例有症状的浆膜下子宫肌瘤患者,均接受超声引导下经皮微波消融。
  • 失访例数:3个月时21例,6个月时34例,12个月时35例。

主要发现

  • 患者平均年龄40.3±4.9岁(范围26-49岁)。
  • 肌瘤平均体积术前221.74±153.18 cm³,术后3个月降至87.24±45.93 cm³(P<.001),6个月降至46.68±24.7 cm³(P<.001),12个月降至38.05±24.93 cm³(P<.001)。
  • 症状严重度评分从治疗前34.53±3.83降至3个月随访时12.74±3.07(P<.001)。
  • 健康相关生活质量评分从治疗前45.25±10.97升至3个月随访时78.48±11.39(P<.001)。
  • 两项评分在6个月和12个月随访时点保持稳定。

关键数值与推荐

  • 疗效依据肌瘤平均体积缩小率及子宫肌瘤症状与生活质量问卷评分在术后3、6、12个月的变化评估。
  • 治疗安全性依据介入放射学会实践指南评估。
  • 术后3、6、12个月肌瘤平均体积均较术前显著缩小(均P<.001)。
  • 术后3个月症状严重度评分显著降低、健康相关生活质量评分显著升高(均P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需更大样本量和设对照组的研究进一步验证。
  • 失访例数较多:3个月时21例、6个月时34例、12个月时35例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To prospectively evaluate the clinical effectiveness and safety of ultrasound-guided percutaneous microwave ablation for symptomatic subserosal uterine myomas. DESIGN: Prospective observational study (Canadian Task Force classification II-1). SETTING: A teaching hospital (Department of Interventional Ultrasound, General Hospital of Chinese PLA, Beijing, China). PATIENTS: Sixty-nine patients with symptomatic subserosal uterine myomas treated with ultrasound-guided percutaneous microwave ablation. INTERVENTIONS: All 69 patients underwent ultrasound-guided percutaneous microwave ablation. The number of patients lost to follow-up at was 21 at 3 months, 34 at 6 months, and 35 at 12 months. MEASUREMENTS AND MAIN RESULTS: The efficacy of treatment was evaluated based the mean myoma volume shrinkage rate and changes in Uterine Fibroid Symptom and Quality of Life Questionnaire scores at 3, 6, and 12 months after therapy. Treatment safety was evaluated based on the Society of Interventional Radiology practice guidelines. The mean patient age was 40.3 ± 4.9 years (range, 26-49 years). The mean myoma volume was 221.74 ± 153.18 cm3 before ablation, decreasing to 87.24 ± 45.93 cm3 at 3 months after ablation (p < .001), 46.68 ± 24.7 cm3 at 6 months after ablation (p < .001), and 38.05 ± 24.93 cm3 at 12 months after ablation (p <.001), respectively. Between pretreatment and 3-month follow-up, the mean symptom severity score decreased from 34.53 ± 3.83 to 12.74 ± 3.07 (p < .001), and the mean health-related quality of life score increased from 45.25 ± 10.97 to 78.48 ± 11.39 (p < .001). Both scores remained stable at the 6- and 12-month follow-up time points. No permanent injury or fatal complications were seen in this series. CONCLUSION: Ultrasound-guided percutaneous microwave ablation of subserosal uterine myomas is a promising treatment method. Further studies with larger sample sizes and a control group are needed.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Yang Y, Hao Y, Zhang J, et al. Ultrasound-Guided Percutaneous Microwave Ablation for Subserosal Uterine Myomas. J Minim Invasive Gynecol. 2018. PMID: 29964178. doi:10.1016/j.jmig.2018.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。